Docoh
Loading...

GLMD Galmed Pharmaceuticals

199 filings

Newest first
Filter options loading...
Top filers
Top filing types
Recent filing years
6-K
GLMD Galmed Pharmaceuticals Ltd
8 Nov 21
Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results
8:25am
6-K
GLMD Galmed Pharmaceuticals Ltd
1 Nov 21
Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study
10:23am
6-K
GLMD Galmed Pharmaceuticals Ltd
12 Oct 21
Results of Galmed’s Phase 2b ARREST Trial of Aramchol Published in Nature Medicine
7:00am
6-K
GLMD Galmed Pharmaceuticals Ltd
31 Aug 21
Current report (foreign)
4:30pm
6-K
GLMD Galmed Pharmaceuticals Ltd
23 Aug 21
Current report (foreign)
4:30pm
6-K
GLMD Galmed Pharmaceuticals Ltd
19 Aug 21
Galmed Pharmaceuticals Announces Publication in “The Journal of Autoimmunity” for its IND ready, Amilo-5MER, a specific anti-inflammatory compound
8:11am
6-K
GLMD Galmed Pharmaceuticals Ltd
16 Aug 21
MHRA Agrees with Galmed’s Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study
8:31am
6-K
2021 Q2
GLMD Galmed Pharmaceuticals Ltd
5 Aug 21
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
7:00am
6-K
GLMD Galmed Pharmaceuticals Ltd
2 Aug 21
FDA Agrees with Galmed’s Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
7:47am
6-K
GLMD Galmed Pharmaceuticals Ltd
19 Jul 21
Current report (foreign)
4:30pm
6-K
GLMD Galmed Pharmaceuticals Ltd
2 Jul 21
Current report (foreign)
4:30pm
6-K
GLMD Galmed Pharmaceuticals Ltd
13 May 21
Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results
8:13am
6-K
GLMD Galmed Pharmaceuticals Ltd
3 May 21
China to Join Galmed's Phase 3 ARMOR Registrational Study for the Treatment of NASH & Fibrosis
8:42am
EFFECT
GLMD Galmed Pharmaceuticals Ltd
2 Apr 21
Notice of effectiveness
12:15am
CORRESP
GLMD Galmed Pharmaceuticals Ltd
31 Mar 21
Correspondence with SEC
8:00pm
UPLOAD
GLMD Galmed Pharmaceuticals Ltd
30 Mar 21
Letter from SEC
8:00pm
6-K
GLMD Galmed Pharmaceuticals Ltd
26 Mar 21
Current report (foreign)
5:11pm
F-3
GLMD Galmed Pharmaceuticals Ltd
26 Mar 21
Shelf registration (foreign)
4:15pm
20-F
2020 FY
GLMD Galmed Pharmaceuticals Ltd
18 Mar 21
Annual report (foreign)
11:29am
6-K
GLMD Galmed Pharmaceuticals Ltd
18 Mar 21
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results
7:29am